Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Moligand™, 10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 5 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Niflumic acid is an inhibitor of cyclooxygenase-2 used for joint and muscular pain.
In vitro
Niflumic acid inhibits Ca2+-activated Cl- channels with inhibition constant of 17 mM. Niflumic acid also inhibits ICl(Ca) elicited by bath application of Ca2+ to oocytes permeabilized using the Ca2+ ionophore A23187, demonstrating that the inhibition of ICl(Ca) is due to a direct interaction with the Cl- channel, rather than by interference with Ca2+ entry through voltage-dependent Ca2+ channels. Niflumic acid blocks Ca2+-activated non-selective cation channels in inside-out patches from the basolateral membrane of rat exocrine pancreatic cells with IC50 of 50 μM. Niflumic acid dose-dependently and reversibly activates large conductance calcium-activated K+ (KCa) channels. Niflumic acid produces a concentration-dependent inhibition of spontaneous transient inward current (STIC, calcium-activated chloride current) amplitude. Niflumic acid inhibits noradrenaline- and caffeine-evoked IO(Ca) with an ICM50 of 6.6 μM, i.e.is less potent against evoked currents compared to spontaneous currents. Niflumic acid voltage-dependently inhibits spontaneous transient inward current (STIC) amplitude with IC50 of 2.3 μM and 1.1 μM at -50 and +50 mV respectively. Niflumic acid inhibits not only IL-13-induced goblet cell hyperplasia but also airway hyperresponsiveness and eosinophilic infiltration. Niflumic suppresses the eotaxin levels in bronchoalveolar lavage fluids and overexpression of the MUC5AC gene, a marker of goblet cell hyperplasia, in the lung after IL-13 instillation. Niflumic acid suppresses JAK2 activation, STAT6 activation, and eotaxin expression in epithelial cells.
In vivo
Cell Data
cell lines:
Concentrations:
Incubation Time:
Powder Purity:≥99%
| Isómeros SMILES | C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F |
|---|---|
| WGK Alemania | 3 |
| RTECS | QT2999100 |
| Peso molecular | 282.22 |
| Beilstein | 22(5)13,598 |
| Reaxy-Rn | 489360 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=489360&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Solubilidad | Solubility (25°C) In vitro DMSO: 66 mg/mL warmed with 50ºC Water: bath (197.54 mM); Ethanol: 20 mg/mL warmed with 50ºC Water: bath (59.86 mM); Water: Insoluble; |
|---|---|
| Punto de fusión (°C) | 203-204 °C |
| 1. Shuai Liu, Keming Zheng, Yilin Jiang, Susu Gai, Bohan Li, Dehai Li, Shuang Yang, Zhihua Lv. (2023) Biotransformation of Penindolone, an Influenza A Virus Inhibitor. MOLECULES, 28 (3): (1479). [PMID:36771146] [10.3390/molecules28031479] |
| 2. Linming Li, Ming Zhang, Dianlong Jia, Zhifang Liu, Ning Zhang, Bin Sun, Zhengping Wang, Min Liu, Qingpeng Wang. (2022) Multi-specific niflumic acid platinum(IV) complexes displaying potent antitumor activities by improving immunity and suppressing angiogenesis besides causing DNA damage. DALTON TRANSACTIONS, 52 (1): (147-158). [PMID:36472127] [10.1039/D2DT03246E] |
| 3. Kai Ni, Bo Che, Rong Gu, Chunhong Wang, Hongyang Xu, Huiduo Li, Shiyan Cen, Mingzhi Luo, Linhong Deng. (2024) BitterDB database analysis plus cell stiffness screening identify flufenamic acid as the most potent TAS2R14-based relaxant of airway smooth muscle cells for therapeutic bronchodilation. Theranostics, [PMID:38389834] [10.7150/thno.92492] |
| 4. Dao-Lai Zhang, Yu-Jing Sun, Ming-Liang Ma, Yi-jing Wang, Hui Lin, Rui-Rui Li, Zong-Lai Liang, Yuan Gao, Zhao Yang, Dong-Fang He, Amy Lin, Hui Mo, Yu-Jing Lu, Meng-Jing Li, Wei Kong, Ka Young Chung, Fan Yi, Jian-Yuan Li, Ying-Ying Qin, Jingxin Li, Alex R B Thomsen, Alem W Kahsai, Zi-Jiang Chen, Zhi-Gang Xu, Mingyao Liu, Dali Li, Xiao Yu, Jin-Peng Sun. (2018) Gq activity- and β-arrestin-1 scaffolding-mediated ADGRG2/CFTR coupling are required for male fertility. eLife, [PMID:29393851] [10.7554/eLife.33432] |
| 5. Yuzhe Wang, Lu sheng, Lin Bu, Huijuan Li, Jianxin Wu, Qing Huang. (2026) A novel epidermal mimicking phospholipid vesicle-based permeation assay: EpiPVPA for in vitro permeation evaluation. INTERNATIONAL JOURNAL OF PHARMACEUTICS, [PMID:41558553] [10.1016/j.ijpharm.2026.126595] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →